{"symbol":"REGN","fiscalQuarter":"Q4-2018","reportDate":"2019-02-06","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2018","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 3.44%","keyNumbers":[{"metric":"EPS","actual":"$6.84","expected":"N/A","surprise":"+16.75%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They noted ongoing investments in research and development.","There was an emphasis on maintaining a competitive edge in the market."],"summary":"Overall, management expressed confidence in the company's product pipeline and future growth. They acknowledged challenges but remain focused on innovation."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported a strong earnings per share, beating expectations by a significant margin. However, the stock fell by 3.44% in reaction, likely due to the lack of revenue details and guidance. Investors may be cautious without clear future projections from management.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2018 earnings: EPS beat by 16.75%. Stock down 3.44%. Full breakdown."}}